ZYBERNO
Stock Report
Updated Aug 31, 2026

KODIAK SCIENCES INC. (KOD)

Healthcare • NASDAQ

$37.72

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
10.0/100
POOR BUSINESS
KODIAK SCIENCES INC. (KOD) scores 10/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-273.2%)
Debt-to-Equity (Solvency Risk):POOR (1.14x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-141.2%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

KODIAK SCIENCES INC. (KOD) stock report — Zyberno Score 10/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, KOD generated -$148.12M in Owner Earnings. Capital was deployed as follows: $1.18M invested in capital expenditures. Reinvestment rate: 9.6%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:37.72
Market Cap:$2.36B

Valuation Multiples (2)

P/B Ratio:38.67x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$2.29B

Price Action & Momentum (3)

Momentum Percentile:100 / 100
% of 52-Week High:78.8%
B. Profitability Assessment

Return Metrics (5)

ROA:-85.5%
Reinvestment Rate:9.6%
Fundamental Growth Rate (g):-13.6%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$11.11
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:1.0%
Latest Earnings Filed:2026-08-13
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.49x
Quick Ratio:2.49x
Cash Ratio:2.39x

Leverage Analysis (3)

Debt To Equity Ttm:1.14x
Debt-to-Equity Ratio:1.14x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:78,588,000.00
Cash And Cash Equivalents:125,903,000.00
Long Term Debt:$42.95M
Net Debt:-$73.15M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$246.42M

Bottom Line Performance (3)

-$241.99M
Income Before Tax:-$229.92M
Ebitda Ttm:-228,586,000.00

Operating Expenses (5)

Operating Expenses:246,420,000.00
R And D Expense:200,599,000.00
Sga Expense:45,821,000.00
Income Tax Expense:$52.00K
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$256.81M
Current Assets:$131.36M
Ppe Net:78,308,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:195,715,000.00
Current Liabilities:52,770,000.00
Long Term Debt:$42.95M
Short Term Debt:$9.81M

Equity & Capital (3)

Equity:$61.10M
Retained Earnings:-$1.68B
Common Stock:490,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:12,639,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:11,608,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$146.94M-$148.12M

Investment Activities (2)

Investing Cash Flow:-$942.00K
Capital Expenditures Ttm:1,178,000.00

Financing Activities (3)

Financing Cash Flow:$619.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:17,834,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-4.19
-$4.19
Earnings Per Share Ttm:-$3.86

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$2.17

Book Value & Capital (2)

Book Value Per Share:$0.98
Cash Per Share:2.01

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$148.12M

Damodaran Growth Analysis (2)

Reinvestment Rate:9.6%
Fundamental Growth Rate (g):-13.6%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-43.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:KOD
Company Name:KODIAK SCIENCES INC.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:62.63M
Shares Outstanding Basic:62.63M
Shares Outstanding Diluted:62.63M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 07:53:58 UTC
Data Timestamp:2026-08-31T07:53:58.895293
Scroll to Top